Niharika B. Mettu

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer

Niharika B. Mettu, Fang‐Shu Ou, Tyler Zemla et al. · JAMA Network Open · 2022 · 117 citations · Full text

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results

Timothy A. Yap, Elisa Fontana, Elizabeth K. Lee et al. · Nature Medicine · 2023 · 94 citations · Full text

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer

Michael J. Overman, Milind Javle, R. Eric Davis et al. · Journal for ImmunoTherapy of Cancer · 2020 · 88 citations · Full text

BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

Niharika B. Mettu, Erin Twohy, Fang‐Shu Ou et al. · Annals of Oncology · 2019 · 72 citations

CT Radiomic Features of Superior Mesenteric Artery Involvement in Pancreatic Ductal Adenocarcinoma: A Pilot Study

Francesca Rigiroli, Jocelyn Hoye, Reginald Lerebours et al. · Radiology · 2021 · 64 citations · Full text